Published in Lancet on February 23, 1979
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery (1991) 1.49
Effect of cyclosporin A on the survival of corneal grafts in rabbits. Br J Ophthalmol (1980) 1.44
Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation (1981) 1.38
Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients. Br Med J (Clin Res Ed) (1982) 1.35
Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant (2009) 1.13
Inhibition by cyclosporin A of rodent malaria in vivo and human malaria in vitro. Infect Immun (1982) 1.10
99mTc-DTPA and 131I-hippuran findings in liver transplant recipients treated with cyclosporin A. Radiology (1982) 0.95
Effect of bile on cyclosporine absorption in dogs. Res Commun Chem Pathol Pharmacol (1986) 0.93
Historic landmarks in clinical transplantation: conclusions from the consensus conference at the University of California, Los Angeles. World J Surg (2000) 0.90
Factors affecting the outcome of corneal transplantation. Ann R Coll Surg Engl (1981) 0.88
Selective induction of immunological tolerance in antiviral T killer cells of inbred mice after treatment with cyclosporin A. Infect Immun (1981) 0.84
Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leuk Lymphoma (2013) 0.84
Stage-selective inhibition of rodent malaria by cyclosporine. Antimicrob Agents Chemother (1988) 0.84
Hepatic and renal function in rats receiving immunotherapeutic doses of cyclosporin A. Br J Exp Pathol (1980) 0.84
Graft-versus-host disease: a review. J R Soc Med (1987) 0.82
Extraction ratio of cyclosporine in a liver transplant patient with organ rejection. J Pharm Sci (1985) 0.81
Liver disease after bone marrow transplantation. Gut (1982) 0.79
A review of the current status and techniques of allogeneic bone marrow transplantation for treatment of leukaemia. J Clin Pathol (1983) 0.78
Effect of cyclosporine on hepatic energy status and on fructose metabolism after portacaval shunt in dog as monitored by phosphorus-31 nuclear magnetic resonance spectroscopy in vivo. Hepatology (1991) 0.77
Treatment of Sézary syndrome with cyclosporin A. J R Soc Med (1983) 0.77
Inhibitory effect of cyclosporin A on peripheral blood and bone marrow T lymphocyte colony formation. Clin Exp Immunol (1981) 0.75
The clearance of cyclosporine by hemodialysis. J Clin Pharmacol (1985) 0.75
Cyclosporin A in clinical organ grafting. First Northern Ireland Kidney Research Fund lecture. Ulster Med J (1981) 0.75
Adult acute leukaemia: prospects for cure. Br Med J (Clin Res Ed) (1981) 0.75
Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta (1986) 13.69
A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res (1982) 7.12
Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet (1990) 7.04
Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol (1981) 6.84
The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J (1973) 5.99
Evolutionary families of peptidases. Biochem J (1993) 5.81
L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J (1982) 5.67
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet (1980) 4.21
Human cathepsin B1. Purification and some properties of the enzyme. Biochem J (1973) 4.06
The electrophoretically 'slow' and 'fast' forms of the alpha 2-macroglobulin molecule. Biochem J (1979) 3.58
Evolutionary families of metallopeptidases. Methods Enzymol (1995) 3.48
Management of adult acute myelogenous leukaemia. Br Med J (1973) 3.33
A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen. Anal Biochem (1979) 3.17
Combined management of malignant teratoma of the testis. Lancet (1979) 3.12
Cathepsin D. Purification of isoenzymes from human and chicken liver. Biochem J (1970) 3.09
Families of serine peptidases. Methods Enzymol (1994) 2.94
A new assay for cathepsin B1 and other thiol proteinases. Anal Biochem (1972) 2.93
Foetal thymic transplant in a case of Digeorge's syndrome. Lancet (1968) 2.85
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
Immunotherapy for acute myelogenous leukaemia. Br J Cancer (1973) 2.67
Cathepsin B1. A lysosomal enzyme that degrades native collagen. Biochem J (1974) 2.65
Cathepsin D. Characteristics of immunoinhibition and the confirmation of a role in cartilage breakdown. Biochem J (1971) 2.60
MEROPS: the peptidase database. Nucleic Acids Res (1999) 2.60
Recognition of leukaemia cells as foreign before and after autoimmunization. Br Med J (1971) 2.50
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol (1982) 2.50
An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature (1998) 2.44
Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum. Biochem J (1983) 2.42
Implantation of a foetal thymus, restoring immunological competence in a patient with thymic aplasia (Digeorge's syndrome). Lancet (1968) 2.40
High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet (1983) 2.33
Five-year analysis of protective isolation. Lancet (1971) 2.31
Pectic polysaccharides of growing plant tissues. Biochem J (1967) 2.24
Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet (1981) 2.22
Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem J (1980) 2.20
Neutral proteinases of human spleen. Purification and criteria for homogeneity of elastase and cathepsin G. Biochem J (1976) 2.17
Human liver cathepsin L. Biochem J (1985) 2.16
Lysosomal acid proteinase of rabbit liver. Biochem J (1967) 2.12
The interaction of alpha2-macroglobulin with proteinases. Binding and inhibition of mammalian collagenases and other metal proteinases. Biochem J (1974) 2.11
Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood (2001) 2.11
The inhibition of tissue acid proteinases by pepstatin. Biochem J (1972) 2.06
Differential diagnosis of malignant lymphoma and nonlymphoid tumors using monoclonal anti-leucocyte antibody. Cancer (1980) 2.05
Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem (1986) 2.03
CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys (1992) 2.03
The place of bone-marrow transplantation in acute myelogenous leukaemia. Lancet (1980) 2.03
Parenteral acyclovir therapy for herpesvirus infections in man. Lancet (1979) 1.99
Hepatitis-associated aplastic anemia. N Engl J Med (1997) 1.98
Families of cysteine peptidases. Methods Enzymol (1994) 1.98
Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child (1972) 1.93
Hypertension and convulsions in children receiving cyclosporin A. Lancet (1982) 1.89
The ICS-'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol (1996) 1.89
Human cathepsin H. Biochem J (1980) 1.88
An improved color reagent for use in Barrett's assay of Cathepsin B. Anal Biochem (1976) 1.87
The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer (1983) 1.84
Action of rat liver cathepsin L on collagen and other substrates. Biochem J (1982) 1.73
Nomenclature and classification of the proteins homologous with the cysteine-proteinase inhibitor chicken cystatin. Biochem J (1986) 1.71
Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia. Lancet (1977) 1.69
Inhibition of cysteine proteinases and dipeptidyl peptidase I by egg-white cystatin. Biochem J (1984) 1.69
MEROPS: the peptidase database. Nucleic Acids Res (2000) 1.69
Human cathepsin G. Catalytic and immunological properties. Biochem J (1976) 1.65
The many forms and functions of cellular proteinases. Fed Proc (1980) 1.64
Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet (1983) 1.64
Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem (1997) 1.63
Chicken alpha2-proteinase inhibitor: a serum protein homologous with ovoinhibitor of egg white. Biochim Biophys Acta (1974) 1.63
Possible lysosomal activation of pancreatic zymogens. Activation of both human trypsinogens by cathepsin B and spontaneous acid. Activation of human trypsinogen 1. Biol Chem Hoppe Seyler (1988) 1.63
The degradation of cartilage proteoglycans by tissue proteinases. Proteoglycan structure and its susceptibility to proteolysis. Biochem J (1977) 1.63
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood (1997) 1.63
Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin. J Biol Chem (1987) 1.61
Human lysosomal elastase. Catalytic and immunological properties. Biochem J (1976) 1.59
The degradation of articular collagen by neutrophil proteinases. Biochim Biophys Acta (1977) 1.59
Lysosomes. Essays Biochem (1976) 1.58
The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun (1984) 1.56
Alpha 2-macroglobulin. Methods Enzymol (1981) 1.55
Human plasma kallikrein. A rapid purification method with high yield. Biochem J (1981) 1.53
Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J Biol Chem (1999) 1.52
Degradation of fructose-1,6-bisphosphate aldolase by cathepsin B. Biochem J (1980) 1.52
Lysis and killing of bacteria by lysosomal proteinases. Infect Immun (1976) 1.50
Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. Br Med J (1973) 1.50
Calpain inhibition by peptide epoxides. Biochem J (1985) 1.49
Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide. Br J Cancer (1978) 1.48
Elastinolytic activity of human cathepsin L. Biochem J (1986) 1.48
The possible role of neutrophil proteinases in damage to articular cartilage. Agents Actions (1978) 1.48
Specific inhibition of cartilage breakdown. Nature (1969) 1.47
The effects of proteolytic enzymes on the mechanical properties of adult human articular cartilage. Biochim Biophys Acta (1976) 1.47
Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood (1999) 1.47
Non-seminoma germ cell tumours (malignant teratoma) of the testis. Results of treatment and an analysis of prognostic factors. Br J Urol (1981) 1.46
Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol (2001) 1.46
Outcome of biphenotypic acute leukemia. Haematologica (1999) 1.46
Purification of cathepsin B by a new form of affinity chromatography. Biochem J (1986) 1.45